Physician profile
Sarah Gilreath
NPI 1134485386
$832.08
in general payments reported to CMS, 2019-2025
14 companies · $135 in 2025
The $135 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $105 · 2022: $453 · 2023: $114 · 2024: $24.64 · 2025: $135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $273.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $217.13 | 2021-2022 | |
| Alkermes, INC. | $175.17 | 2022-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $100.52 | 2022-2023 | Uzedy, Austedo Xr, Austedo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $69.51 | 2023-2025 | Caplyta |
| Ironshore Pharmaceuticals INC. | $48.73 | 2021-2022 | |
| Corium, LLC | $32.36 | 2022 | |
| Qol Medical, LLC | $32.19 | 2022 | |
| Sobi, INC | $31.95 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.46 | 2021 | |
| Tris Pharma INC | $22.84 | 2022 | |
| Janssen Pharmaceuticals, INC | $22.19 | 2023 | Invega Trinza, Invega Sustenna |
| E.R. Squibb & Sons, L.L.C. | $19.45 | 2025 | Cobenfy |
| Adlon Therapeutics L.P. | $17.11 | 2021 | |
| Indivior INC. | $13.47 | 2023 | Perseris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Gilreath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.